Oxford BioDynamics demonstrates PSE test’s potential in prostate cancer screening
The minimally invasive PSE test was built using the EpiSwitch 3D genomics platform and methodology of Oxford BioDynamics
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
07 Feb 23
The minimally invasive PSE test was built using the EpiSwitch 3D genomics platform and methodology of Oxford BioDynamics
07 Feb 23
Completion of enrollment for this 225-subject study is a key milestone on the path to delivering the first…
07 Feb 23
Completion of enrollment for this 225-subject study is a key milestone on the path to delivering the first…
07 Feb 23
The company has said that it will have an additional announcement soon regarding when the NES Reprocessed Eagle…
06 Feb 23
The expanded FDA approval enhances the intended patient population that can be treated using SPRINT PNS System to…
06 Feb 23
LithoVue Elite System is a new-generation single-use digital ureteroscope designed based on the company’s StoneSmart technology platform and…
06 Feb 23
The high-throughput single-cell multiomics platform will support accelerating discovery across immunology, genetic disease research, and cancer and chronic…
06 Feb 23
NEUROMARK is intended to disrupt the parasympathetic nerve signals that can cause an inflammatory reaction in the target…
06 Feb 23
The Ablamap® Software was used to detect sources of AF among these persistent/long-standing persistent AF patients who had…
03 Feb 23
TactiFlex Ablation Catheter, SE, is claimed to be the world’s first and only ablation catheter with a flexible…